Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 243

The DOI matches its Crossref record.

Design and analysis of non‐inferiority mortality trials in oncology

Rothmann, Mark, Li, Ning, Chen, Gang, Chi, George Y. H., Temple, Robert, Tsou, Hsiao‐Hui · 2003 · Statistics in Medicine

Abstract

The recent revision of the Declaration of Helsinki and the existence of many new therapies that affect survival or serious morbidity, and that therefore cannot be denied patients, have generated increased interest in active‐control trials, particularly those intended to show equivalence or non‐inferiority to the active‐control. A non‐inferiority hypothesis has historically been formulated in terms of a fixed margin. This margin was historically designed to exclude a ‘clinically meaningful difference’, but has become recognized that the margin must also be no larger than the assured effect of the control in the new study. Depending on how this ‘assured effect’ is determined or estimated, the selected margin may be very small, leading to very large sample sizes, especially when there is an added requirement that a loss of some specified fraction of the assured effect must be ruled out. In cases where it is appropriate, this paper proposes non‐inferiority analyses that do not involve a fixed margin, but can be described as a two confidence interval procedure that compares the 95 per cent two‐sided CI for the difference between the treatment and the control to a confidence interval for the control effect (based on a meta‐analysis of historical data comparing the control to placebo) that is chosen to preserve a study‐wide type I error rate of about 0.025 (similar to the usual standard for a superiority trial) for testing for retention of a prespecified fraction of the control effect. The approach assumes that the estimate of the historical active‐control effect size is applicable in the current study. If there is reason to believe that this effect size is diminished (for example, improved concomitant therapies) the estimate of this historical effect could be reduced appropriately. The statistical methodology for testing this non‐inferiority hypothesis is developed for a hazard ratio (rather than an absolute difference between treatments, because a hazard ratio seems likely to be less population dependent than the absolute difference). In the case of oncology, the hazard ratio is the usual way of comparing treatments with respect to time to event (time to progression or survival) endpoints. The proportional hazards assumption is regarded as reasonable (approximately holding). The testing procedures proposed are conditionally equivalent to two confidence interval procedures that relax the conservatism of two 95 per cent confidence interval testing procedures and preserve the type I error rate at a one‐sided 0.025 level. An application of this methodology to Xeloda, a recently approved drug for the treatment of metastatic colorectal cancers, is illustrated. Other methodologies are also described and assessed – including a point estimate procedure, a Bayesian procedure and two delta‐method confidence interval procedures. Published in 2003 by John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/sim.1400

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 243

Metadata

Authors
Rothmann, M., Li, N., Chen, G., Chi, G. Y. H., Temple, R., & Tsou, H.
Venue
Statistics in Medicine
Publisher
Wiley
Published
2002-12-18
Volume
22
Issue
2
Pages
239-264
ISSN
  • 0277-6715 (ISSN-L)
  • 1097-0258
OpenAlex
W2145774014
Cited by
243
References
0
FWCI
12.60
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Design and analysis of non‐inferiority mortality trials in oncology. https://app.cochat.ai/papers/10.1002/sim.1400
The paper
Rothmann, M., Li, N., Chen, G., Chi, G. Y. H., Temple, R., & Tsou, H. (2003). Design and analysis of non‐inferiority mortality trials in oncology. Statistics in Medicine. https://doi.org/10.1002/sim.1400

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.